quinta-feira, 8 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 18, 2026

Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3

View original at globenewswire.com
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Venglustat has the potential to slow the progression of Gaucher disease type 3 by inhibiting abnormal accumulation of glycosphingolipids and its pathophysiological consequences

    60% confidence

  • Venglustat works by reducing abnormal accumulation of glycosphingolipids and is designed to cross the blood-brain barrier to target the underlying pathology causing neurological effects of GD3

    60% confidence

  • Sanofi will continue to collaborate with the FDA to advance this potential therapeutic option

    60% confidence

  • There is currently no approved treatment for the neurological symptoms of Gaucher disease type 3

    60% confidence

  • There is no approved treatment for neurological symptoms of Gaucher disease type 3

    60% confidence

  • This regulatory milestone recognizes the significant unmet medical need for people living with Gaucher disease type 3, particularly those experiencing progressive neurological deterioration

    60% confidence

  • This regulatory milestone recognizes the significant unmet medical need for people living with Gaucher disease type 3, particularly those experiencing progressive neurological deterioration

    60% confidence

  • Venglustat was generally well tolerated with no new safety signals compared to previous studies

    60% confidence

  • The positive results from the LEAP2MONO study are an encouraging advance in the research and development process, and we will continue to collaborate with the FDA to advance this potential treatment option

    60% confidence

  • The positive results from the LEAP2MONO study are an encouraging advancement in the research and development process

    60% confidence

  • Venglustat was generally well tolerated with no new safety signals compared to previous studies

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 — Source | Via News | pt.VIA.NEWS